Cannabidiol (CBD) represents a new promising drug due to a wide spectrum of pharmacological actions. In order to relate CBD clinical efficacy to its pharmacological mechanisms of action, we performed a bibliographic search on PUBMED about all clinical studies investigating the use of CBD as a treatment of psychiatric symptoms. Findings to date suggest that (a) CBD may exert antipsychotic effects in schizophrenia mainly through facilitation of endocannabinoid signalling and cannabinoid receptor type 1 antagonism; (b) CBD administration may exhibit acute anxiolytic effects in patients with generalised social anxiety disorder through modification of cerebral blood flow in specific brain sites and serotonin 1A receptor agonism; (c) CBD may reduce withdrawal symptoms and cannabis/tobacco dependence through modulation of endocannabinoid, serotoninergic and glutamatergic systems; (d) the preclinical pro-cognitive effects of CBD still lack significant results in psychiatric disorders. In conclusion, current evidences suggest that CBD has the ability to reduce psychotic, anxiety and withdrawal symptoms by means of several hypothesised pharmacological properties. However, further studies should include larger randomised controlled samples and investigate the impact of CBD on biological measures in order to correlate CBD's clinical effects to potential modifications of neurotransmitters signalling and structural and functional cerebral changes.

Pharmacological properties of cannabidiol in the treatment of psychiatric disorders : a critical overview / G.M. Mandolini, M. Lazzaretti, A. Pigoni, L. Oldani, G. Delvecchio, P. Brambilla. - In: EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES. - ISSN 2045-7960. - 27:4(2018), pp. 327-335.

Pharmacological properties of cannabidiol in the treatment of psychiatric disorders : a critical overview

G.M. Mandolini;A. Pigoni;L. Oldani;G. Delvecchio;P. Brambilla
2018

Abstract

Cannabidiol (CBD) represents a new promising drug due to a wide spectrum of pharmacological actions. In order to relate CBD clinical efficacy to its pharmacological mechanisms of action, we performed a bibliographic search on PUBMED about all clinical studies investigating the use of CBD as a treatment of psychiatric symptoms. Findings to date suggest that (a) CBD may exert antipsychotic effects in schizophrenia mainly through facilitation of endocannabinoid signalling and cannabinoid receptor type 1 antagonism; (b) CBD administration may exhibit acute anxiolytic effects in patients with generalised social anxiety disorder through modification of cerebral blood flow in specific brain sites and serotonin 1A receptor agonism; (c) CBD may reduce withdrawal symptoms and cannabis/tobacco dependence through modulation of endocannabinoid, serotoninergic and glutamatergic systems; (d) the preclinical pro-cognitive effects of CBD still lack significant results in psychiatric disorders. In conclusion, current evidences suggest that CBD has the ability to reduce psychotic, anxiety and withdrawal symptoms by means of several hypothesised pharmacological properties. However, further studies should include larger randomised controlled samples and investigate the impact of CBD on biological measures in order to correlate CBD's clinical effects to potential modifications of neurotransmitters signalling and structural and functional cerebral changes.
antianxiety agents; antipsychotics; clinical drug studies; drugs new; psychopharmacology
Settore MED/25 - Psichiatria
2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
mandolini2018 (1).pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 159.83 kB
Formato Adobe PDF
159.83 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
pharmacological_properties_of_cannabidiol_in_the_treatment_of_psychiatric_disorders_a_critical_overview.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 159.78 kB
Formato Adobe PDF
159.78 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/660215
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 53
  • ???jsp.display-item.citation.isi??? 42
social impact